Matthew Gline Biography and Net Worth

CEO of Roivant Sciences

Matt Gline serves as Chief Executive Officer of Roivant Sciences. Mr. Gline joined Roivant in March 2016 and previously served as Chief Financial Officer. From April 2014 to March 2016, he was a Vice President at Goldman Sachs, Fixed Income Digital Structuring, where he focused on technology and data strategy.

Prior to Goldman Sachs, Mr. Gline was a co-founder of Fourthree, a risk analytics technology and consulting company. From 2008 to 2012, he served as Vice President at Barclays, Enterprise Risk Management Advisory, where he provided analysis for corporate clients related to capital markets access for financing and risk management. Mr. Gline earned his A.B. in Physics from Harvard College.

What is Matthew Gline's net worth?: The estimated net worth of Matthew Gline is at least $206.76 million as of September 23rd, 2024. Mr. Gline owns 17,870,543 shares of Roivant Sciences stock worth more than $206,762,183 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Gline may own. Additionally, Mr. Gline receives a salary of $1,770,000.00 as CEO at Roivant Sciences. Learn More about Matthew Gline's net worth.
How old is Matthew Gline?: Mr. Gline is currently 40 years old. There are 5 older executives and no younger executives at Roivant Sciences. Learn More on Matthew Gline's age.
What is Matthew Gline's salary?: As the CEO of Roivant Sciences Ltd., Mr. Gline earns $1,770,000.00 per year. Learn More on Matthew Gline's salary.
How do I contact Matthew Gline?: The corporate mailing address for Mr. Gline and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Matthew Gline's contact information.
Has Matthew Gline been buying or selling shares of Roivant Sciences?: Matthew Gline has not been actively trading shares of Roivant Sciences within the last three months. Most recently, Matthew Gline sold 1,983,257 shares of the business's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $11.79, for a transaction totalling $23,382,600.03. Following the completion of the sale, the chief executive officer now directly owns 17,870,543 shares of the company's stock, valued at $210,693,701.97. Learn More on Matthew Gline's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Matthew Gline (CEO), Rakhi Kumar (CAO), Keith Manchester (Director), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, insiders at the sold shares 9 times. They sold a total of 7,186,843 shares worth more than $82,463,515.47. The most recent insider tranaction occured on December, 18th when CIO Mayukh Sukhatme sold 412,584 shares worth more than $4,971,637.20. Insiders at Roivant Sciences own 7.9% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 12/18/2024.

Matthew Gline Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/23/2024	Sell	1,983,257	$11.79	$23,382,600.03	17,870,543
10/25/2022	Sell	19,276	$4.40	$84,814.40	1,164,009
9/23/2022	Sell	21,053	$3.07	$64,632.71	1,183,285
8/24/2022	Sell	20,009	$3.71	$74,233.39	1,204,338
7/25/2022	Sell	20,455	$4.33	$88,570.15	1,224,347
6/23/2022	Sell	19,855	$4.34	$86,170.70	1,244,802
5/20/2022	Sell	139,791	$3.70	$517,226.70	1,264,657
4/25/2022	Sell	8,509	$3.84	$32,674.56	1,404,448
3/30/2022	Sell	33,686	$4.84	$163,040.24
3/25/2022	Sell	35,386	$5.06	$179,053.16
3/18/2022	Sell	82,006	$5.13	$420,690.78
3/7/2022	Sell	92,324	$5.52	$509,628.48

Matthew Gline Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $11.57

$11.41

$11.67

50 Day Range

MA: $11.91

$11.16

$12.71

2 Week Range

Now: $11.57

$9.69

$13.06

Volume

15,754,118 shs

Average Volume

5,795,466 shs

Market Capitalization

$8.42 billion

P/E Ratio

2.05

Dividend Yield

N/A

Beta

1.25

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Click here now for the urgent details.

Matthew Gline Biography and Net Worth

What is Matthew Gline's net worth?

How old is Matthew Gline?

What is Matthew Gline's salary?

How do I contact Matthew Gline?

Has Matthew Gline been buying or selling shares of Roivant Sciences?

Who are Roivant Sciences' active insiders?

Are insiders buying or selling shares of Roivant Sciences?